Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Jun;117(7):845-52.
doi: 10.1111/j.1471-0528.2010.02564.x. Epub 2010 Apr 19.

High fever following postpartum administration of sublingual misoprostol

Affiliations
Free PMC article
Multicenter Study

High fever following postpartum administration of sublingual misoprostol

J Durocher et al. BJOG. 2010 Jun.
Free PMC article

Abstract

Objective: To explore what triggers an elevated body temperature of > or =40.0 degrees C in some women given misoprostol, a prostaglandin E1 analogue, for postpartum haemorrhage (PPH).

Design: Post hoc analysis.

Setting: One tertiary-level hospital in Quito, Ecuador.

Population: A cohort of 58 women with a fever of above 40 degrees C following treatment with sublingual misoprostol (800 micrograms) for PPH.

Methods: Side effects were documented for 163 Ecuadorian women given sublingual misoprostol to treat their PPH. Women's body temperatures were measured, and if they had a fever of > or =40.0 degrees C, measurements were taken hourly until the fever subsided. Temperature trends were analysed, and the possible physiological mechanisms by which postpartum misoprostol produces a high fever were explored.

Main outcome measures: The onset, duration, peak temperatures, and treatments administered for cases with a high fever.

Results: Fifty-eight of 163 women (35.6%) treated with misoprostol experienced a fever of > or =40.0 degrees C. High fevers followed a predictable pattern, often preceded by moderate/severe shivering within 20 minutes of treatment. Body temperatures peaked 1-2 hours post-treatment, and gradually declined over 3 hours. Fevers were transient and did not lead to any hospitalisation. Baseline characteristics were comparable among women who did and did not develop a high fever, except for known previous PPH and time to placental expulsion.

Conclusions: An unexpectedly high rate of elevated body temperature of > or =40.0 degrees C was documented in Ecuador following sublingually administered misoprostol. It is unclear why temperatures > or =40.0 degrees C occurred with a greater frequency in Ecuador than in other study populations using similar treatment regimens for PPH. Pharmacogenetic studies may shed further light on variations in individuals' responses to misoprostol.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean misoprostol plasma concentrations after sublingual administration of misoprostol (800 micrograms), and mean temperatures of 58 cases of high fever over time.

Similar articles

Cited by

References

    1. Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007 DOI: 10.1002/14651858.CD000494.pub3. - DOI - PubMed
    1. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007 DOI: 10.1002/14651858.CD003249.pub2. - DOI - PubMed
    1. Hofmeyr GJ, Gülmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22:1025–41. - PubMed
    1. WHO Department of Reproductive Health and Research . WHO statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment. WHO; 2009.
    1. Hofmeyr GJ, Gülmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta–analysis of maternal deaths and dose–related effects. Bull World Health Organ. 2009;87:666–77. - PMC - PubMed

Publication types